Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, June 26, 2024 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 14,361,113 shares of its common stock at a price to the public of $2.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,972,221 shares of its common stock at an offering price of $2.249 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering at the public offering price, less the underwriting discount. The gross proceeds from the offering to Taysha are expected to be approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriter’s option to purchase additional shares. The offering is expected to close on or about June 27, 2024, subject to customary closing conditions.